Muscle loss may predict biologic drug success in IBD patients
NCT ID NCT07482163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how common muscle loss (sarcopenia) is in people with inflammatory bowel disease (IBD) using CT scans. Researchers want to see if muscle loss changes how well biologic treatments work. About 50 adults with IBD who have received biologic therapy will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CT-ASSESSED SARCOPENIA OUTCOMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Could IBD medications during pregnancy shape a Child's development?
- Can AI learn to grade endoscopy quality from video?
- Can a gentler iron pill break the anemia cycle in IBD?
- Could relaxation techniques ease gut disorders? new study investigates
- Scientists investigate gut-healing protein in Crohn's and colitis